GSK Investigational Site

Bardejov 8501

0 studies enrolling now · 3 studies all time

What they study most

Cough, Neoplasms, Breast, Pulmonary Disease, Chronic Obstructive, Refractory Chronic Cough

Studies at this site

• A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Running, not enrolling
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed